Search

Your search keyword '"Ledgerwood JE"' showing total 128 results

Search Constraints

Start Over You searched for: Author "Ledgerwood JE" Remove constraint Author: "Ledgerwood JE"
128 results on '"Ledgerwood JE"'

Search Results

3. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

4. A monovalent chimpanzee adenovirus Ebola vaccine — preliminary report

6. P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)

8. Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.

9. Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.

10. Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.

11. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.

12. Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.

13. High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.

14. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.

15. Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.

16. Vaccine elicitation and structural basis for antibody protection against alphaviruses.

17. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.

18. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans.

19. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.

20. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.

21. Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings.

22. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.

23. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.

24. Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.

25. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.

26. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.

27. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.

28. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.

29. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.

30. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.

31. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.

32. Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans.

33. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.

34. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.

35. A Monoclonal Antibody for Malaria Prevention.

36. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.

37. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.

38. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.

39. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

40. Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.

41. A sensitive method to quantify HIV-1 antibodies in mucosal samples.

42. A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies.

43. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

44. Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants.

45. Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients.

46. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

47. Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach.

48. Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions.

49. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.

50. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

Catalog

Books, media, physical & digital resources